If this SRI abstract was in relation to ovarian mouse cancer then NRT at 19 cents could be about about right. A remedy for refractory human cancer in an animal model should be pulling a lot more than that given nothing else appears to exist that can claim this. I think that most of us would agree.
So remission of refractory human cancer and prevention of recurrance in a human ... does $19 sound close? Maybe $190???
That's one BIG wedge heading our way. Is there a T/A label for that kind of whopper?
- Forums
- ASX - By Stock
- KZA
- SRI abstract
SRI abstract, page-19
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)